MTOR and breast cancer: Our results from previous and current studies indicated that while GW405833 suppressed breast cancer MDA‐MB‐231 survival and interfered with its interaction with osteoblasts, GW405833 supported osteoblast cell survival, potentially through the differential effects of GW405833 on the PI3K/AKT/mTOR pathway in these cells.